Phase III trial of doxorubicin (A)/cyclophosphamide (C) (AC), docetaxel (D), and alternating AC and D (AC-D) as front-line chemotherapy for metastatic breast cancer (MBC): Japan Clinical Oncology Group trial (JCOG9802)

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 521-521 ◽  
Author(s):  
N. Katsumata ◽  
H. Minami ◽  
K. Aogi ◽  
T. Tabei ◽  
M. Sano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Phase Iii ◽  
Oncology Group ◽  
Front Line ◽  
Japan Clinical Oncology Group ◽  
Phase Iii Trial ◽  
Group Trial ◽  
Line Chemotherapy

scholarly journals Southwest Oncology Group (SWOG)

2006 ◽  
Vol 9 (S1) ◽  
pp. 442-463
Author(s):  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Metastatic Breast Cancer ◽  
High Risk ◽  
Adjuvant Therapy ◽  
Metastatic Breast ◽  
Phase Iii ◽  
Oncology Group ◽  
Phase Iii Trial ◽  
Southwest Oncology Group

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Southwest Oncology Group (SWOG). Clinical trials include: Docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER-2 positive, stage IV breast cancer. S0215Phase III trial of continuous schedule AC + G versus q 2-week schedule AC, followed by paclitaxel given either q 2 weeks or weekly for 12 weeks as post-operative adjuvant therapy in node-positive or high-risk node-negative breast cancer. S0221Phase III randomized trial of anastrozole versus anastrozole and fulves-trant as first line therapy for postmenopausal women with metastatic breast cancer. S0226Phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer. S0230Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer. S0307Phase II trial of simple oral therapy (continuous oral cyclophosphamide and capecitabine) in patients with metastatic breast cancer. S0430A phase II study of goserelin plus anastrozole for the treatment of male patients with hormone-receptor positive metastatic or recurrent breast cancer. S0511Randomized placebo-controlled biomarker modulation trial using celecoxib in premenopausal women at high risk for breast cancer. Phase IIb. S0300

Sign in / Sign up

Export Citation Format

Share Document